Close Menu

NEW YORK (GenomeWeb) – Exact Sciences announced before the opening of the market on Friday that it is offering $190 million in aggregate principal amount of its 1.0 percent convertible senior notes due 2025. The firm said it expects the offering to provide gross proceeds of $202.4 million.

Exact upsized the offering Friday after originally announcing a $150 million offering after the close of the market on Thursday. The initial public offering price for the Notes will be 106.5 percent of face value plus accrued interest from Jan. 17.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.